insiderwall
Menu
SuperinvestorInsider
Novavax Inc. NVAX

Super Investor & Insider

Nessuna transazione insider negli ultimi 6 mesi.

Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.

About

Novavax Inc. is a biotechnology company specializing in the discovery, development, and commercialization of recombinant vaccines to address serious infectious diseases. The company focuses on using a proprietary recombinant nanoparticle technology platform combined with advanced adjuvants to generate robust immune res

SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees749
TickerNVAX

Statistics

Market Cap$1.56B
Revenue (TTM)$1.12B
Net Income$440.3M
Net Margin39.2%
EPS$2.58
P/E3.63
P/S2.49
P/B-10.18
EV/EBITDA16.62
ROE-344.7%
Dividend Yield
Price$9.50

Data: Twelve Data · Revenue = mcap / P/S